Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Sep 30, 2023
Vertex Pharmaceuticals reported revenue for the quarter that rose compared to the same quarter one year earlier, but slipped slightly from the immediately preceding quarter. The sequential decline interrupted a multi-quarter trend of successive increases.
Key takeaway
Quarter ended Sep 30, 2023 · FY2023 Q3
Vertex Pharmaceuticals reported revenue for the quarter that rose compared to the same quarter one year earlier, but slipped slightly from the immediately preceding quarter. The sequential decline interrupted a multi-quarter trend of successive increases.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
-0.4%
Change from the immediately preceding quarter.
Year-over-year
+6.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $2.3B | +11.1% |
| Mar 31, 2023 | $2.4B | +13.2% |
| Jun 30, 2023 | $2.5B | +13.5% |
| Sep 30, 2023 | $2.5B | +6.4% |
Revenue performance
Revenue for the quarter was lower than the prior three-month period, marking the first sequential decline in recent quarters. Compared to the same period a year ago, revenue was higher.
Quarterly comparison
Relative to the immediately preceding quarter, revenue decreased fractionally. Compared with the same quarter one year earlier, revenue showed a larger increase.
What to watch
The slight sequential revenue decline may warrant monitoring for any change in underlying demand or product mix dynamics.